Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vaginal nifedipine ointment is a compounded topical formulation containing 0.2% nifedipine in a lanolin and mineral oil base. Developed by Vanderbilt University, it was investigated as an adjunctive treatment to pelvic floor physical therapy for female patients suffering from levator ani syndrome (also known as levator myalgia) and pelvic floor hypertonus. Nifedipine is a dihydropyridine calcium channel blocker that acts by inhibiting the influx of calcium ions into smooth and skeletal muscle cells, thereby promoting muscle relaxation and reducing associated pelvic pain, dyspareunia, and dysfunctional voiding. A randomized controlled trial (NCT01586286) was designed to evaluate its efficacy, but the study was ultimately withdrawn before enrollment began.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vaginal nifedipine ointment.